Robustness of Tricuspid Regurgitation Reduction at 1 year Following Edge-to-edge Repair for Primary Tricuspid Regurgitation

Overview

Journal Clin Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Sep 24

PMID 39316085

Authors

Felix Rudolph

Muhammed Gercek

Johannes Kirchner

Maria Ivannikova

Kai P Friedrichs

Tanja K Rudolph

Volker Rudolph

Martin Andreas

Anna Bartunek

Philipp E Bartko

Varius Dannenberg

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Within recent years, transcatheter tricuspid edge-to-edge repair (T-TEER) has emerged as a safe and effective treatment option in patients with secondary tricuspid regurgitation (TR). However, for primary TR, data on the robustness and durability of TR reduction 1 year following T-TEER is limited.

Methods: All consecutive patients treated with T-TEER for TR at two high-volume centers between September 2018 and December 2022 were enrolled in a registry. Primary TR was defined as tricuspid valve (TV) prolapse or flail TV leaflets as assessed by pre- and peri-interventional transesophageal echocardiography (TEE).

Results: 201 patients were included in this analysis, of whom 27 (13.4%) were classified as primary TR and 174 (86.6%) as TR of secondary origin. All-cause mortality during 1-year follow-up was reached by 50 patients (24.9%) [primary: 7 (25.9%), secondary: 43 (24.7%)], and 151 (75.1%) completed follow-up with transthoracic echocardiography (TTE). Patients' median age was 80 (76-83) years, 112 (55.7%) were female and 181 (90.1%) reported a New-York heart association functional class (NYHA-FC) of III or IV. The remaining baseline clinical and echocardiographic parameters were comparable between the groups, but secondary TR patients had a significantly higher TRI-SCORE (5 (4-8) vs. 7 (5-14), P = 0.010). In both groups, an immediate reduction of TR-Grade post-intervention was observed. This reduction was sustained at follow-up with 80.0% of the primary TR patients classified as moderate or less and 61.8% of the secondary TR patients. This translated to a significant improvement of NHYA-FC in both groups. Kaplan-Meier analysis revealed no differences regarding rates for all-cause mortality between the groups (P < 0.99).

Conclusion: T-TEER achieves a robust TR reduction in primary TR patients 1 year after intervention with noninferior clinical results to treatment for secondary TR with regards to mortality, re-hospitalization, and NYHA-FC.

References

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J . 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021; 43(7):561-632. DOI: 10.1093/eurheartj/ehab395. View

Welle G, Hahn R, Lindenfeld J, Lin G, Nkomo V, Hausleiter J . New Approaches to Assessment and Management of Tricuspid Regurgitation Before Intervention. JACC Cardiovasc Interv. 2024; 17(7):837-858. DOI: 10.1016/j.jcin.2024.02.034. View

Andreas M, Burri H, Praz F, Soliman O, Badano L, Barreiro M . Tricuspid valve disease and cardiac implantable electronic devices. Eur Heart J. 2023; 45(5):346-365. PMC: 10834167. DOI: 10.1093/eurheartj/ehad783. View

Dannenberg V, Bartko P, Andreas M, Bartunek A, Goncharov A, Gercek M . Tricuspid edge-to-edge repair for tricuspid valve prolapse and flail leaflet: feasibility in comparison to patients with secondary tricuspid regurgitation. Eur Heart J Cardiovasc Imaging. 2023; 25(3):365-372. PMC: 10883724. DOI: 10.1093/ehjci/jead264. View

Lorinsky M, Belanger M, Shen C, Markson L, Delling F, Manning W . Characteristics and Significance of Tricuspid Valve Prolapse in a Large Multidecade Echocardiographic Study. J Am Soc Echocardiogr. 2020; 34(1):30-37. PMC: 7796941. DOI: 10.1016/j.echo.2020.09.003. View

Otto C, Nishimura R, Bonow R, Carabello B, Erwin 3rd J, Gentile F . 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 143(5):e35-e71. DOI: 10.1161/CIR.0000000000000932. View

Topilsky Y, Maltais S, Inojosa J, Oguz D, Michelena H, Maalouf J . Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting. JACC Cardiovasc Imaging. 2018; 12(3):433-442. DOI: 10.1016/j.jcmg.2018.06.014. View

Prihadi E, Delgado V, Leon M, Enriquez-Sarano M, Topilsky Y, Bax J . Morphologic Types of Tricuspid Regurgitation: Characteristics and Prognostic Implications. JACC Cardiovasc Imaging. 2019; 12(3):491-499. DOI: 10.1016/j.jcmg.2018.09.027. View

Hahn R, Abraham T, Adams M, Bruce C, Glas K, Lang R . Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr. 2013; 26(9):921-64. DOI: 10.1016/j.echo.2013.07.009. View

10.

Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28(1):1-39.e14. DOI: 10.1016/j.echo.2014.10.003. View

11.

Dannenberg V, Koschutnik M, Dona C, Nitsche C, Mascherbauer K, Heitzinger G . Invasive Hemodynamic Assessment and Procedural Success of Transcatheter Tricuspid Valve Repair-Important Factors for Right Ventricular Remodeling and Outcome. Front Cardiovasc Med. 2022; 9:891468. PMC: 9200997. DOI: 10.3389/fcvm.2022.891468. View

12.

Andreas M, Russo M, Taramasso M, Zuber M, Mascherbauer J . Novel transcatheter clip device (MitraClip XTR) enables significant tricuspid annular size reduction. Eur Heart J Cardiovasc Imaging. 2019; 20(9):1070. DOI: 10.1093/ehjci/jez032. View

13.

Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P . Transcatheter Repair for Patients with Tricuspid Regurgitation. N Engl J Med. 2023; 388(20):1833-1842. DOI: 10.1056/NEJMoa2300525. View

14.

Gercek M, Narang A, Korber M, Friedrichs K, Puthumana J, Ivannikova M . GLIDE Score: Scoring System for Prediction of Procedural Success in Tricuspid Valve Transcatheter Edge-to-Edge Repair. JACC Cardiovasc Imaging. 2024; 17(7):729-742. DOI: 10.1016/j.jcmg.2024.04.008. View

15.

Messika-Zeitoun D, Thomson H, Bellamy M, Scott C, Tribouilloy C, Dearani J . Medical and surgical outcome of tricuspid regurgitation caused by flail leaflets. J Thorac Cardiovasc Surg. 2004; 128(2):296-302. DOI: 10.1016/j.jtcvs.2004.01.035. View

16.

Praz F, Muraru D, Kreidel F, Lurz P, Hahn R, Delgado V . Transcatheter treatment for tricuspid valve disease. EuroIntervention. 2021; 17(10):791-808. PMC: 9724890. DOI: 10.4244/EIJ-D-21-00695. View

17.

Bernal J, Ponton A, Diaz B, Llorca J, Garcia I, Sarralde A . Surgery for rheumatic tricuspid valve disease: a 30-year experience. J Thorac Cardiovasc Surg. 2008; 136(2):476-81. DOI: 10.1016/j.jtcvs.2008.02.065. View

18.

Gercek M, Rudolph V . Secondary Tricuspid Regurgitation: Pathophysiology, Incidence and Prognosis. Front Cardiovasc Med. 2021; 8:701243. PMC: 8339586. DOI: 10.3389/fcvm.2021.701243. View

19.

Addetia K, Harb S, Hahn R, Kapadia S, Lang R . Cardiac Implantable Electronic Device Lead-Induced Tricuspid Regurgitation. JACC Cardiovasc Imaging. 2019; 12(4):622-636. DOI: 10.1016/j.jcmg.2018.09.028. View

20.

Ruf T, Gossler T, von Bardeleben R . Understanding Atrial Fibrillation and Atrial Secondary Tricuspid Regurgitation: The Chicken or the Egg?. J Am Coll Cardiol. 2022; 80(24):2299-2300. DOI: 10.1016/j.jacc.2022.10.009. View